Date: 15 October 2018

TO WHOM IT MAY CONCERN

DALTEPARIN SODIUM INJECTION BP 2019

RELATED SUBSTANCES

There is an error in the limits published in the Related substances test for Dalteparin Sodium Injection in the BP 2019 which will be revised at the earliest opportunity.

The limits will be amended as follows:

LIMITS

In the chromatogram obtained with solution (2):
the area of the peak due to dermatan sulfate/chondroitin sulfate is not greater than 0.3 times the area of the corresponding peak in the chromatogram obtained with solution (6) (2.0%);
no peaks other than the peak due to dermatan sulfate and chondroitin sulfate are detected.

Please accept this as a letter of intent on behalf of the British Pharmacopoeia Commission.

If you have any questions concerning this letter, please do not hesitate to contact the British Pharmacopoeia Secretariat at the address above.

Yours faithfully,

[Signature]

MR JAMES POUND
Secretary & Scientific Director
E-mail: BPCOM@mhra.gov.uk